These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33080748)

  • 1. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
    Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
    Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The successful posterior sectionectomy accompanied with caudate lobectomy for hepatocellular carcinoma located in segment 1 after LEN-TACE: a case report.
    Nanashima A; Hamada T; Hiyoshi M; Imamura N; Tsuchimochi Y; Shimizu I; Nagata K; Kawakami H
    Clin J Gastroenterol; 2024 Jun; 17(3):490-496. PubMed ID: 38353862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline evaluation: Atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria.
    Kimura M; Nishikawa K; Imamura J; Kimura K
    Cancer Med; 2024 Sep; 13(18):e70217. PubMed ID: 39300938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Mimura T; Minami A; Momose K; Hirano H; Tanaka M; Ueda Y; Tai K; Yasuhara Y; Nakagawa D; Yamamoto A; Kido M; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 Jul; 44(7):3097-3103. PubMed ID: 38925835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
    Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
    Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
    Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
    Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
    Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
    Kobayashi S; Fukushima T; Ueno M; Moriya S; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Suzuki M; Uojima H; Hidaka H; Kusano C; Suzuki M; Morimoto M
    BMC Cancer; 2022 May; 22(1):517. PubMed ID: 35525913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
    Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
    J Formos Med Assoc; 2024 Jul; 123(7):788-795. PubMed ID: 38310071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
    Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.
    Bai Z; Yu X; Tang Q; Zhang R; Shi X; Liu C
    Br J Hosp Med (Lond); 2024 Jul; 85(7):1-12. PubMed ID: 39078898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.